Clinical Trials Browser

Phase 1/2 × Unknown × Bendamustine Hydrochloride × Clear all

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT01412307 2015-08-11

LEBEN

Phase 1/2 Unknown

Hodgkin Disease

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01686386 2013-04-05

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT01221103 2011-09-13

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01002703 2011-08-12

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell